Investor Presentaiton

Oncology Opdivo Opdualag TIGIT Bispecific DGK Inhibitor AR LDD Continuing to grow Opdivo / Dual 10 26 OPDIVO approvals 10 YERVOY approvals 11 Metastatic Setting Tumor/Trial Status Tumor/Trial Subcutaneous nivolumab CM-67T 2023 MSI-H CRC Readout CM-8HW Opdivo + Yervoy 1L MIUC CM-901 Opdivo + Yervoy vs SOC chemo Early-Stage Setting Tumor/Trial NSCLC (Peri-Adj) CM-77T Neo-adj Opdivo + chemo followed by Adj Opdivo vs chemo NSCLC (Adj) ANVIL Opdivo vs Observation 2024 Readout 1L HCC CM-9DW Opdivo + Yervoy vs sorafenib / lenvima Status Tumor/Trial 2024 Readout NSCLC Stage 3 (Unresectable) CM-73L 2024 Readout Opdivo mono, O+Y vs Imfinzi HCC (Adj) CM-9DX Opdivo vs Placebo Status 2025 Readout 2025 Readout Status 2025 Readout 2025 Readout MIBC (Peri-Adj) tumors CA017-078 Bristol Myers Squibb™ Opdivo+chemo vs chemo 2024 Readout Not for Product Promotional Use 95

View entire presentation